Los Angeles Capital Management’s Abeona Therapeutics ABEO Stock Holding History

Los Angeles Capital Management’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$150K	Sell	33,561 -121,425	-78%	-$607K	﹤0.01%	1219
2025 Q4	$787K	Sell	154,986 -52,791	-25%	-$266K	﹤0.01%	728
2025 Q3	$1.1M	Sell	207,777 -60,371	-23%	-$383K	﹤0.01%	679
2025 Q2	$1.52M	Buy	+268,148	New	+$1.53M	0.01%	516
2021 Q3	–	Sell	-3,087	Closed	-$120K	–	1461
2021 Q2	$120K	Sell	3,087 -15,354	-83%	-$626K	﹤0.01%	1507
2021 Q1	$867K	Buy	18,441 +5,215	+39%	+$287K	﹤0.01%	960
2020 Q4	$519K	Buy	13,226 +3,357	+34%	+$114K	﹤0.01%	1192
2020 Q3	$252K	Buy	9,869 +4,031	+69%	+$254K	﹤0.01%	1324
2020 Q2	$425K	Buy	+5,838	New	+$404K	﹤0.01%	1173

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Los Angeles Capital Management's ABEO Position: Q1 2026 in Review

Los Angeles Capital Management reduced its Abeona Therapeutics (ABEO) stake by 78% in Q1 2026, selling an estimated $607K and leaving 33,561 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #1219.

Los Angeles Capital Management first reported a position in ABEO in Q2 2020 and has held it in 9 quarters since. The position peaked at $1.52M in Q2 2025. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

Los Angeles Capital Management held 33,561 shares of Abeona Therapeutics worth $150K as of Q1 2026.
Los Angeles Capital Management sold 121,425 Abeona Therapeutics shares in Q1 2026, an estimated $607K.
Abeona Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q1 2026, its #1219 holding.
Los Angeles Capital Management first reported a position in Abeona Therapeutics in Q2 2020 and has held it in 9 quarters since.
Los Angeles Capital Management's Abeona Therapeutics position peaked at $1.52M in Q2 2025.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on Los Angeles Capital Management's 13F filing for Q1 2026, filed 8 May 2026.